Under normal circumstances, the coagulation system is balanced in favour of
anticoagulation.
Thrombin is the key effector enzyme of the clotting cascade.
Antagonists of vitamin K inhibit a vitamin-K-dependent post-translational m
odification of several coagulation proteins, which is required for these pr
oteins to attain a phospholipid-binding conformation.
Heparin stimulates the activity of antithrombin, a serine-protease inhibito
r.
Analysis of knock-out mice has shown the relative importance of the coagula
tion factors in vivo.
Gene therapy may soon be a therapeutic option for inherited deficiencies of
factors VIII and IX.